Head-to-head · Value Score
bmiMD vs Wisp
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, Wisp a 75. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameWisp
#139 · Grade C+ · Fair Price
Est. first month
From $99/mo (starting dose, brand-name)
The verdict
bmiMD takes it on Value Score, 89 to 75 — an est. $99/mo first month, with no teaser step-up baked in. Wisp isn't out of it: Shoppers who want branded injectables plus a sublingual semaglutide alternative.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | Wisp |
|---|---|---|
| Value Score | 89 (A) | 75 (C+) |
| Est. first month | $99/mo | From $99/mo (starting dose, brand-name) |
| Save vs brand-name | ~93% | — |
| Semaglutide | $99/mo | From $225/mo (compounded oral) |
| Tirzepatide | $139/mo | From $99/mo (starting dose, brand-name) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
Wisp
Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.
Why it's a deal
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
The fine print
- Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
- Pharmacy partners not named
- States served not listed publicly
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to Wisp.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.